AstraZeneca’s Forxiga approved in EU to treat symptomatic chronic heart failure

By NS Healthcare Staff Writer

08 Feb 23

Forxiga is already approved in more than 100 countries worldwide, to treat patients with type-2 diabetes (T2D), HFrEF…

PharmaceuticalsRegulation

Clexio partners with Genetika+ for antidepressant screening platform

By NS Healthcare Staff Writer

07 Feb 23

Genetika+ platform allows assessment of the functional effects of drugs directly on human neurons and comprises more than…

PharmaceuticalsPartnerships and Licensing Agreements

Gilead secures FDA nod for Trodelvy to treat metastatic breast cancer

By NS Healthcare Staff Writer

06 Feb 23

Trodelvy is a Trop-2 directed antibody-drug conjugate, indicated for previously treated patients with metastatic hormone receptor (HR)-positive, human…

PharmaceuticalsRegulation

US FDA approves Tezspire for self-administration using pre-filled pen

By NS Healthcare Staff Writer

03 Feb 23

Tezspire is a human monoclonal antibody that inhibits the action of TSLP, a key epithelial cytokine that plays…

PharmaceuticalsDrug Delivery Systems

GSK’s Jesduvroq approved in US to treat CKD-related anaemia in dialysis patients

By NS Healthcare Staff Writer

02 Feb 23

The US FDA approval of Jesduvroq is based on results from the ASCEND-D trial, which evaluated the efficacy…

PharmaceuticalsRegulation

Kite, Arcellx close deal to develop T-cell therapy for multiple myeloma

By NS Healthcare Staff Writer

31 Jan 23

The collaboration aims to co-develop and co-commercialise Arcellx’s late-stage product candidate CART-ddBCMA, a T-cell therapy that uses Arcellx’s…

PharmaceuticalsPartnerships and Licensing Agreements

Lilly unit secures US FDA approval for Jaypirca to treat MCL in adults

By NS Healthcare Staff Writer

30 Jan 23

Jaypirca is the first BTK inhibitor specifically approved for patients with mantle cell lymphoma previously treated with a…

PharmaceuticalsRegulation

Enhertu approved in EU to treat HER2-low metastatic breast cancer

By NS Healthcare Staff Writer

27 Jan 23

The EC approval is based on results from Phase 3 DESTINY-Breast04 clinical trial, in which Enhertu reduced the…

PharmaceuticalsRegulation

Lilly to invest $450m to expand its Research Triangle Park facility in US

By Vidya Sagar

25 Jan 23

The US drugmaker intends to start initial production from the expanded Research Triangle Park this year, with full…

PharmaceuticalsManufacturing

Takeda signs licensing deal with HUTCHMED for rights to fruquintinib outside China

By NS Healthcare Staff Writer

24 Jan 23

The licensing agreement for fruquintinib, which provides a potential new treatment option for patients with refractory metastatic colorectal…

PharmaceuticalsPartnerships and Licensing Agreements